US 12,391,734 B2
PD-1 homing endonuclease variants, compositions, and methods of use
Jasdeep Mann, Seattle, WA (US); Joel Gay, Seattle, WA (US); Jordan Jarjour, Seattle, WA (US); and Joy Zhang, Seattle, WA (US)
Assigned to REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US)
Filed by REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US)
Filed on Feb. 22, 2024, as Appl. No. 18/584,363.
Application 18/584,363 is a continuation of application No. 17/738,484, filed on May 6, 2022, granted, now 11,912,746.
Application 17/738,484 is a continuation of application No. 16/330,039, granted, now 11,365,226, issued on Jun. 21, 2022, previously published as PCT/US2017/050774, filed on Sep. 8, 2017.
Claims priority of provisional application 62/414,279, filed on Oct. 28, 2016.
Claims priority of provisional application 62/385,079, filed on Sep. 8, 2016.
Prior Publication US 2024/0301018 A1, Sep. 12, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/47 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/36 (2025.01); A61K 40/42 (2025.01); C12N 15/86 (2006.01)
CPC C07K 14/4702 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/36 (2025.01); A61K 40/4211 (2025.01); A61K 40/4215 (2025.01); C12N 15/86 (2013.01); C07K 2319/80 (2013.01)] 27 Claims
 
1. A polypeptide comprising an I-OnuI homing endonuclease (HE) variant that cleaves a target site in the human program cell death 1 (PD-1) gene, wherein the I-OnuI HE variant comprises the amino acid sequence set forth in any one of SEQ ID NOs: 11, 12, 60, 62, and 63.